Imunon, Inc. (0HUZ.L)
USD 0.88
(-5.44%)
USD 0.88
(-5.44%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.13 Million USD | -75.29% |
| 2022 | 4.61 Million USD | -21.24% |
| 2021 | 5.85 Million USD | 48.8% |
| 2020 | 3.93 Million USD | -50.59% |
| 2019 | 7.96 Million USD | -15.44% |
| 2018 | 9.41 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 2.35 Million USD | -61.18% |
| 2014 | 6.05 Million USD | 21.06% |
| 2013 | 5 Million USD | 36.57% |
| 2012 | 3.66 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1 Million USD | 0.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 FY | 1.13 Million USD | -75.29% |
| 2023 Q3 | 1.26 Million USD | 16.97% |
| 2023 Q2 | 1.08 Million USD | -72.24% |
| 2023 Q1 | 3.89 Million USD | -15.44% |
| 2023 Q4 | 1.13 Million USD | -10.02% |
| 2022 Q3 | 5.31 Million USD | -10.52% |
| 2022 Q1 | 5.89 Million USD | 0.77% |
| 2022 Q4 | 4.61 Million USD | -13.32% |
| 2022 FY | 4.61 Million USD | -21.24% |
| 2022 Q2 | 5.94 Million USD | 0.77% |
| 2021 Q1 | 3.25 Million USD | -29.99% |
| 2021 FY | 5.85 Million USD | 48.8% |
| 2021 Q2 | 5.76 Million USD | 77.22% |
| 2021 Q3 | 5.8 Million USD | 0.79% |
| 2021 Q4 | 5.85 Million USD | 0.79% |
| 2020 Q2 | 6.54 Million USD | -24.47% |
| 2020 Q4 | 4.64 Million USD | -14.78% |
| 2020 FY | 3.93 Million USD | -50.59% |
| 2020 Q1 | 8.66 Million USD | -4.87% |
| 2020 Q3 | 5.45 Million USD | -16.71% |
| 2019 Q2 | 10.95 Million USD | -0.01% |
| 2019 FY | 7.96 Million USD | -15.44% |
| 2019 Q4 | 9.1 Million USD | -12.19% |
| 2019 Q3 | 10.37 Million USD | -5.3% |
| 2019 Q1 | 10.95 Million USD | 16.31% |
| 2018 Q2 | 9.22 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 9.41 Million USD | 0.0% |
| 2018 Q4 | 9.41 Million USD | 1.05% |
| 2018 Q3 | 9.31 Million USD | 1.06% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | -100.0% |
| 2016 Q1 | 1.31 Million USD | -43.86% |
| 2016 FY | - USD | -100.0% |
| 2016 Q4 | - USD | 0.0% |
| 2015 Q4 | 2.35 Million USD | -29.72% |
| 2015 Q3 | 3.34 Million USD | -21.99% |
| 2015 Q2 | 4.28 Million USD | -17.38% |
| 2015 Q1 | 5.18 Million USD | -14.29% |
| 2015 FY | 2.35 Million USD | -61.18% |
| 2014 Q4 | 6.05 Million USD | -12.12% |
| 2014 Q3 | 6.88 Million USD | -12.46% |
| 2014 Q2 | 7.86 Million USD | 72.52% |
| 2014 Q1 | 4.56 Million USD | -8.78% |
| 2014 FY | 6.05 Million USD | 21.06% |
| 2013 Q1 | 3.17 Million USD | -13.32% |
| 2013 FY | 5 Million USD | 36.57% |
| 2013 Q3 | 2.34 Million USD | -17.58% |
| 2013 Q2 | 2.84 Million USD | -10.26% |
| 2013 Q4 | 5 Million USD | 113.04% |
| 2012 Q4 | 3.66 Million USD | 0.0% |
| 2012 FY | 3.66 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 99.124% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 98.001% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.706% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 97.507% |
| bluebird bio, Inc. | 224.41 Million USD | 99.492% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 96.927% |
| Editas Medicine, Inc. | 24.37 Million USD | 95.325% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.991% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 99.942% |
| Myriad Genetics, Inc. | 130.9 Million USD | 99.13% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.559% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 96.568% |
| Verastem, Inc. | 40.08 Million USD | 97.158% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.986% |
| Waters Corporation | 2.3 Billion USD | 99.951% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.996% |
| Biogen Inc. | 7.18 Billion USD | 99.984% |
| Nektar Therapeutics | 112.62 Million USD | 98.988% |
| Perrigo Company plc | 3.63 Billion USD | 99.969% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.549% |
| Illumina, Inc. | 1.48 Billion USD | 99.923% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 64.822% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -13.929% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.344% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 95.16% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.808% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 96.601% |
| Evolus, Inc. | 120.35 Million USD | 99.053% |
| Adicet Bio, Inc. | 17.7 Million USD | 93.564% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | 62.938% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.958% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.773% |
| FibroGen, Inc. | 89.69 Million USD | 98.73% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.958% |
| OPKO Health, Inc. | 222.03 Million USD | 99.487% |
| Homology Medicines, Inc. | 43.17 Million USD | 97.361% |
| Geron Corporation | 35.05 Million USD | 96.75% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.951% |
| Exelixis, Inc. | 189.94 Million USD | 99.4% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -21.719% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 98.822% |
| Zoetis Inc. | 6.56 Billion USD | 99.983% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.36% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 74.119% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.843% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 96.668% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.919% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.899% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.924% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.814% |
| Insmed Incorporated | 1.19 Billion USD | 99.905% |
| TG Therapeutics, Inc. | 100.11 Million USD | 98.862% |
| Incyte Corporation | 29.16 Million USD | 96.093% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 99.745% |